Stemtech Stock Today
| STEK Stock | USD 0.0006 0.0001 14.29% |
PerformanceWeakest
| Odds Of DistressLow
|
Stemtech is selling for 6.0E-4 as of the 24th of January 2026. This is a 14.29% down since the beginning of the trading day. The stock's last reported lowest price was 5.0E-4. Stemtech has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 26th of October 2025 and ending today, the 24th of January 2026. Click here to learn more.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. The company has 48.63 M outstanding shares. More on Stemtech
Moving against Stemtech OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Stemtech OTC Stock Highlights
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Drug Manufacturers—Specialty & Generic, Healthcare, Computing (View all Sectors) |
Stemtech [STEK] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stemtech's market, we take the total number of its shares issued and multiply it by Stemtech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Stemtech conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 48.63 M outstanding shares.
Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Stemtech Probability Of Bankruptcy
Ownership AllocationStemtech shows a total of 48.63 Million outstanding shares. Stemtech has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 63.6 % of Stemtech outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Stemtech Ownership Details
Stemtech Risk Profiles
| Mean Deviation | 10.05 | |||
| Standard Deviation | 13.56 | |||
| Variance | 184.0 | |||
| Risk Adjusted Performance | (0.11) |
Stemtech Stock Against Markets
Picking the right benchmark for Stemtech otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Stemtech otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Stemtech is critical whether you are bullish or bearish towards Stemtech at a given time. Please also check how Stemtech's historical prices are related to one of the top price index indicators.
Stemtech OTC Stock Analysis Notes
About 64.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Stemtech is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Stemtech contact Charles Arnold at 954 715 6000 or learn more at https://www.stemtech.com.Stemtech Investment Alerts
| Stemtech generated a negative expected return over the last 90 days | |
| Stemtech has high historical volatility and very poor performance | |
| Stemtech has some characteristics of a very speculative penny stock | |
| Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 64.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Dynatronics enters Chapter 7 bankruptcy and liquidation - TipRanks |
Stemtech Thematic Classifications
In addition to having Stemtech otc stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | ITInformation technology and IT services |
Stemtech Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stemtech's market, we take the total number of its shares issued and multiply it by Stemtech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Stemtech Profitablity
Stemtech's profitability indicators refer to fundamental financial ratios that showcase Stemtech's ability to generate income relative to its revenue or operating costs. If, let's say, Stemtech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Stemtech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Stemtech's profitability requires more research than a typical breakdown of Stemtech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.85) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.34) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.34. Technical Drivers
As of the 24th of January, Stemtech has the Coefficient Of Variation of (607.60), risk adjusted performance of (0.11), and Variance of 184.0. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stemtech, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Stemtech, which can be compared to its competition.Stemtech Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Stemtech Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Stemtech price patterns.
Stemtech Outstanding Bonds
Stemtech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Stemtech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Stemtech bonds can be classified according to their maturity, which is the date when Stemtech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| STLA 1711 29 JAN 27 Corp BondUS85855CAA80 | View | |
| STLA 2691 15 SEP 31 Corp BondUS85855CAB63 | View | |
| STLA 5625 12 JAN 28 Corp BondUS85855CAD20 | View | |
| STLA 6375 12 SEP 32 Corp BondUS85855CAE03 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Stemtech Predictive Daily Indicators
Stemtech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Stemtech otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 62056.83 | |||
| Daily Balance Of Power | (1.00) | |||
| Rate Of Daily Change | 0.86 | |||
| Day Median Price | 6.0E-4 | |||
| Day Typical Price | 6.0E-4 | |||
| Period Momentum Indicator | (0.0001) |
Stemtech Forecast Models
Stemtech's time-series forecasting models are one of many Stemtech's otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Stemtech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Stemtech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Stemtech Corporate Management
Elected by the shareholders, the Stemtech's board of directors comprises two types of representatives: Stemtech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stemtech. The board's role is to monitor Stemtech's management team and ensure that shareholders' interests are well served. Stemtech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stemtech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Arnold | CEO Director | Profile | |
| James Cardwell | Chief Officer | Profile | |
| Alejandro Carrillo | Managing Markets | Profile | |
| John Meyer | COO Pres | Profile |
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.